share_log

艾美疫苗：董事會會議通告

AIM VACCINE: NOTICE OF BOARD MEETING

香港交易所 ·  Mar 15 04:30
Summary by Moomoo AI
艾美疫苗股份有限公司宣布，將於2024年3月27日（星期三）召開董事會會議，主要議程包括考慮及批准公司及其附屬公司截至2023年12月31日止年度的年度業績及其發佈。會議同時將考慮建議派發末期股息（如有）。董事會成員包括執行董事周延先生、關文先生及賈紹君先生；非執行董事周杰先生、周欣先生、趙繼臣先生及王愛軍女士；以及獨立非執行董事。會議由董事會主席、執行董事兼首席執行官周延先生主持。
艾美疫苗股份有限公司宣布，將於2024年3月27日（星期三）召開董事會會議，主要議程包括考慮及批准公司及其附屬公司截至2023年12月31日止年度的年度業績及其發佈。會議同時將考慮建議派發末期股息（如有）。董事會成員包括執行董事周延先生、關文先生及賈紹君先生；非執行董事周杰先生、周欣先生、趙繼臣先生及王愛軍女士；以及獨立非執行董事。會議由董事會主席、執行董事兼首席執行官周延先生主持。
AMIE VACCINES CO., LTD. ANNOUNCES THAT A BOARD MEETING WILL BE HELD ON WEDNESDAY, MARCH 27, 2024. THE MAIN AGENDA INCLUDES CONSIDERATION AND APPROVAL OF THE COMPANY AND ITS SUBSIDIARIES AND THEIR RELEASE OF THE ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023. The meeting will also consider the proposed distribution of a final dividend (if any). The members of the Board of Directors include Executive Directors Mr. Zhou Yan, Mr. Guan Man and Mr. Jia Shao-chun; Non-Executive Directors Mr. Zhou Jie, Mr. Zhou Xin, Mr. Zhao Jichun and Ms. Wang Aijun; and Independent Non-Executive Directors. The meeting was chaired by Mr. Zhou Yan, Chairman of the Board, Executive Director and Chief Executive Officer.
AMIE VACCINES CO., LTD. ANNOUNCES THAT A BOARD MEETING WILL BE HELD ON WEDNESDAY, MARCH 27, 2024. THE MAIN AGENDA INCLUDES CONSIDERATION AND APPROVAL OF THE COMPANY AND ITS SUBSIDIARIES AND THEIR RELEASE OF THE ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023. The meeting will also consider the proposed distribution of a final dividend (if any). The members of the Board of Directors include Executive Directors Mr. Zhou Yan, Mr. Guan Man and Mr. Jia Shao-chun; Non-Executive Directors Mr. Zhou Jie, Mr. Zhou Xin, Mr. Zhao Jichun and Ms. Wang Aijun; and Independent Non-Executive Directors. The meeting was chaired by Mr. Zhou Yan, Chairman of the Board, Executive Director and Chief Executive Officer.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more